Global Acute Repetitive Seizures Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2030 - (By Drug Type Coverage, By Route of Administration Coverage, By Distribution Channel Coverage, By End-use Coverage, By Geographic Coverage and Leading Companies)
Published Date: Oct 2023 |
Format:
| No. of Pages: 240
The global acute repetitive seizures market that was worth around US$0.9 Bn in 2022 will possibly reach a valuation of US$13.5 Bn by the end of 2030. Between the years of forecast, the market size will exhibit a staggering CAGR of more than 30%.
Pfizer, GlaxoSmithKline, Novartis, Neurelis, Inc., NeuroPace, Inc., Takeda Pharmaceuticals, and Sage Therapeutics are some of the biggest names in this industry.
Currently, North America holds the largest share of the global acute repetitive seizures market.
The primary factors projected to drive the acute repetitive seizures market expansion are the presence of a strong pipeline, increasing initiatives for R&D, and the presence of a treatment gap in adequate seizure control.
The oral route of administration remains prominent, whereas the antiepileptic drugs (AEDs) category continues to account for the largest revenue share of the acute repetitive seizures market.
Buy now
Quality assured
Report Description
Research Methodology
